Rapid Novor
Rapid Novor, Inc. is the world's leader in antibody protein sequencing technology. Specializing in the field of mass spectrometry-based proteomics, the team has developed the technology to directly sequence antibody proteins without needing access to the producing cell line. As a University of Waterloo spin-off, the company continues to build its technology portfolios based on the twenty years of scientific research and inventions from Dr. Bin Ma, co-founder and chief scientist. The company's REmAb™ antibody protein sequencing service has allowed for the accurate sequencing of any given antibody proteins on a routine basis in high throughput manner. The company's WILD™ service is the first commercially available service that can accurately distinguish the isobaric Isoleucine and Leucine using mass spectrometry.
About Rapid Novor
Founded
2015Estimated Revenue
$1M-$10MEmployees
51-250Funding / Mkt. Cap
$5MCategory
Sector
Health CareIndustry Group
Pharmaceuticals, Biotechnology & Life SciencesIndustry
BiotechnologySIC Code
87NAICs Code
541Location
City
KitchenerState
OntarioCountry
CanadaRapid Novor
Find your buyer within Rapid Novor